RESEARCH

Autologous bone marrow-derived mononuclear cell therapy in three patients with severe asthma

Fabio S. Aguiar, André S. Melo, Ana Maria S. Araújo, Alexandre P. Cardoso, Sergio Augusto L. de Souza, Miquelias Lopes-Pacheco, Fernanda F. Cruz, Debora G. Xisto, Karina D. Asensi, Lanuza Faccioli, Anna Beatriz S. Salgado, Maria Carolina P. P. Landesmann, Regina C. S. Goldenberg, Bianca Gutfilen, Marcelo M. Morales, Patricia R. M. Rocco, and Jose R. Lapa e Silva

Abstract

Background: Despite recent advances in understanding its pathophysiology and development of novel therapies, asthma remains a serious public health issue worldwide. Combination therapy with inhaled corticosteroids and long-acting β2-adrenergic agonists results in disease control for many patients, but those who exhibit severe asthma are often unresponsive to conventional treatment, experiencing worse quality of life, frequent exacerbations, and increasing healthcare costs. Bone marrow-derived mononuclear cell (BMMC) transplantation has been shown to reduce airway inflammation and remodeling and improve lung function in experimental models of allergic asthma.

Methods: This is a case series of three patients who presented severe asthma, unresponsive to conventional therapy and omalizumab. They received a single intravenous dose of autologous BM2MCs (2 × 10^7) and were periodically evaluated for 1 year after the procedure. Endpoint assessments included physical examination, quality of life questionnaires, imaging (computed tomography, single-photon emission computed tomography, and ventilation/perfusion scan), lung function tests, and a 6-min walk test.

Results: All patients completed the follow-up protocol. No serious adverse events attributable to BMMC transplantation were observed during or after the procedure. Endpoint assessments included physical examination, quality of life questionnaires, imaging (computed tomography, single-photon emission computed tomography, and ventilation/perfusion scan), lung function tests, and a 6-min walk test.

Conclusions: This paper described for the first time the effects of BMMC therapy in patients with severe asthma, providing a basis for subsequent trials to assess the efficacy of this therapy.

Keywords: Asthma, Bone marrow mononuclear cells, Cell therapy, Autologous transplantation, Lung
Background
Asthma is a chronic inflammatory disease that represents an increasing public health issue worldwide, affecting 1–18% of the population in different countries [1]. It is characterized by airflow obstruction with airway inflammation and hyper-responsiveness [2]. Most patients with asthma achieve disease control with a combination of inhaled corticosteroids and long-acting β2-adrenoceptor agonists (LABAs). However, a substantial proportion of patients with severe asthma are unresponsive to these treatments, experiencing unsuccessful control of their symptoms, pulmonary exacerbations, and accelerated deterioration of lung function [1, 2].

A growing body of evidence suggests that cell-based therapies hold therapeutic promise for patients with lung diseases. Bone marrow-derived mononuclear cells (BMMCs) and mesenchymal stromal cells (MSCs), administered either locally or systemically, have yielded favorable therapeutic outcomes in a wide spectrum of experimental models [3–5]. In animal models of allergic asthma, cell-based therapies reduced airway inflammation and remodeling significantly, thus improving lung function [4, 6–11]. Furthermore, we previously found that in a model of ovalbumin-induced allergic asthma, BMMCs induced better therapeutic responses compared to MSCs in some endpoint assessments, including reduction of alveolar collapse area and collagen fiber content in lung tissue [10]. Autologous BMMCs can also be transplanted on the same day of harvesting, thus avoiding additional costs related to cell culture procedures and potential host-recipient mismatch complications, such as graft-versus-host disease.

In early-stage clinical studies, BMMC therapy demonstrated a safety profile in patients with idiopathic dilated cardiomyopathy, ischemic stroke, or silicosis [12–14]. We described three patients with severe asthma unresponsive to conventional treatment (corticosteroids, LABA, muscarinic antagonists) and omalizumab who received autologous transplantation of BMMCs intravenously. These patients were followed up periodically for 1 year after the procedure. Endpoint assessments included physical examination, quality of life (QoL) questionnaires, imaging (computed tomography (CT), single-photon emission computed tomography (SPECT), and ventilation/perfusion scan), lung function tests, and a 6-min walk test (6MWT). BMMCs were characterized on the basis of a fibroblast colony-forming assay and expression of specific surface antigens by flow cytometry analysis.

Material and methods
Ethics statement
Patients were recruited from the Severe Asthma Reference Center at the Institute of Thoracic Diseases, Clementino Fraga Filho University Hospital (HUCFF), Federal University of Rio de Janeiro (UFRJ), Brazil. All patients were investigated and treated in accordance with the Global Initiative for Asthma (GINA) guidelines [1]. The patients also received standard care according to the institutional protocol of the HUCFF/UFRJ Pulmonary Division, before and after autologous transplantation of BMMCs. The study protocol and informed consent form were approved by the Brazilian National Research Ethics Committee (CONEP; study ID number: 06503212.3.0000.5257).

Study population
Ten patients with severe asthma were initially screened for eligibility. The inclusion criteria were (1) age between 18 and 65 years; (2) uncontrolled asthma despite maximum therapy in the previous 6 months, as recommended by the GINA guidelines [1]; (3) unresponsiveness to immunobiological therapy with omalizumab; (4) a forced expiratory volume in 1 s (FEV1) < 80% on spirometry and a bronchodilator response at any time; and (5) informed consent to participate in the study. The exclusion criteria were (1) an infectious episode in the 4 weeks preceding enrollment; (2) other lung diseases, including active tuberculosis; (3) current or recent smoking (within 12 months of inclusion), characterized by tobacco intake greater than 10 pack-years; (4) any malignant neoplasm; (5) autoimmune diseases; (6) hematologic or cardiovascular diseases; (7) seropositivity for the human immunodeficiency virus; (8) pregnancy; and (9) participation in any other clinical trial. Based on these criteria, three women were included in the study.

Bone marrow aspiration, cell separation, and labeling
The bone marrow was aspirated under local anesthesia from the posterior iliac crest as previously described [12, 13]. BMMCs were isolated by density gradient on Ficoll-Paque at 400 g for 30 min (Ficoll-Paque Plus 1.077, 1:2, Amersham Biosciences, São Paulo, Brazil), washed twice in saline, and resuspended in saline solution with 10% autologous serum. After washing and counting, a total of 2 × 10⁷ cells were labeled with technetium-99m (⁹⁹mTc) for tracking after infusion, as described elsewhere [12, 13]. Cell viability was assessed by the trypan blue exclusion test before and after labeling and was estimated to be greater than 93% in all cases. All procedures for cell preparation and labeling were carried out under sterile conditions in a laminar flow hood. Bacteriological analyses and cultures were also performed to exclude any contamination of the specimens.

Flow cytometry analysis
Total bone marrow and BMMCs were characterized by flow cytometry using specific surface antigens. Briefly, cells were incubated for 20 min at room temperature
with primary antibodies conjugated with fluorescein isothiocyanate (FITC), phycoerythrin (PE), allophycocyanin (APC), peridinin chlorophyll protein (PerCP), phycoerythrin cyan 5 (PE-Cy5), and phycoerythrin cyan 7 (PE-Cy7). After staining, erythrocytes were lysed with BD (Becton Dickinson) FACS Lysing Solution. Data acquisition was performed on a FACS ARIA II (BD Biosciences) flow cytometer and analyzed in Infinity software (Cytognos, Spain). The panel of markers tested included CD45 FITC (clone H130, BD), CD13 PE (clone WM15, BD Pharmingen), CD11b APC (clone MEM-174, Exbio), CD34 FITC (clone 8G12, BD Biosciences), CD117 PE (clone YB5.88, BD Pharmingen), HLA-DR PE-Cy5 (clone TU36, BD Pharmingen), CD45 APC (clone MEM-28, Exbio), CD64 FITC (clone 10.1, BD Pharmingen), CD34 PE (clone 8G12, BD Biosciences), CD14 PE (clone MoP9, BD Pharmingen), CD20 FITC (clone LT20, Exbio), CD10 PE (clone MEM-78, Exbio), CD19APC (clone HIB19, BD Pharmingen), CD45 APC-Cy7 (clone 2D1, BD Pharmingen), lineage cocktail 2 (LIN2, composed of CD3, CD14, CD19, CD20, and CD56; clones SK7, MoP9, SJ25Cl, L27, and NCAM16.2, respectively, BD Biosciences), CD105 PE (clone P9, SJ25C1, L27, and NCAM16.2, respectively, BD Pharmingen), CD73 APC (clone AD2, BD Pharmingen), LymphoGram™ (composed of CD8 + CD19 FITC, CD3 + CD56 PE, and CD4 PE-Cy5; clones UCH-T4, H5D7, 33-2-A3, C5.9, 13B8.2 respectively, Cytognos), CD36 PE (clone CB38, BD Pharmingen), and CD71 APC (clone M-A712, BD Pharmingen).

Fibroblast colony-forming unit assay
A fibroblast colony-forming assay was performed to determine the presence of putative progenitor cells of mesenchymal lineages. After Ficoll-Paque centrifugation, mononuclear cells were counted and plated in triplicate in a 6-well plate. A total of 2 × 10⁶ cells was cultured in each well using high-glucose Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (Gibco) and 10⁻⁶ M hydrocortisone. After plating, cells were maintained in a humidified incubator (37°C, 5% CO₂) for 1 week without any manipulation. Then, 50% of the medium was replaced and cells were maintained under the same conditions for an additional week. At the end of this protocol, cells were stained with Giemsa and colonies were counted.

BMMC transplantation and imaging
A 20-mL aliquot of the autologous BMMC solution (2 × 10⁷ cells labeled with ⁹⁹mTc) was injected into a peripheral vein of the upper arm of each patient. After the procedure, patients were monitored for 1 h and then transferred to the Nuclear Medicine Department for further analyses. Whole-body, planar, and tomographic scintigraphy was carried out 2 h after BMMC transplantation. For regional analysis in both the anterior (A) and posterior (P) images, rectangular regions of interest, equal in size, were drawn over the whole lung. Both lungs had six regions of interest: right upper, right middle, right lower, left upper, left middle, and left lower lung fields. Regional blood flow was evaluated by ⁹⁹mTc macroaggregated albumin (⁹⁹mTc-MAA) perfusion scintigraphy in each area of interest and calculated as previously described [15]. Patients were followed for a further 12 months after BMMC transplantation.

Measured variables
Patient demographics, medical history, vital signs, routine laboratory tests (blood counts, coagulation tests, biochemical measurements, liver function tests), electrocardiogram, the Modified Borg Dyspnea Scale, and the 6-min walk test (6MWT) were assessed using standardized clinical report forms. Lung function tests, including spirometry, lung CT scans, and ventilation/perfusion scintigraphy, were also performed. Quality of life (QoL) was assessed with the Saint George’s Respiratory Questionnaire (SGRQ) [16], which is a standardized set of self-report measures for assessment of impaired health and perceived well-being in patients with lung diseases. Measurements were performed before BMMC transplantation (baseline) and at 7, 30, 60, 120, 180, and 360 days after the procedure.

Results
Bone marrow aspiration and cellular characterization
The bone marrow was aspirated from the posterior iliac crest of patients (volume = 160.5 ± 51.7 mL; number of collected cells = 8.8 × 10¹⁰ ± 1.0 × 10¹⁰; cell viability = 94.3 ± 1.2%) and prepared for separation, characterization, and transplantation. Tables 1 and 2 depict, respectively, cell populations in total bone marrow and BMMCs obtained after separation. The total bone marrow was mainly composed of neutrophils (~ 70%), while a significant increase in mononuclear cell populations, including T lymphocytes (35.5%), helper T cells (13%), and cytotoxic T cells (9.5%), was observed after density gradient on Ficoll-Paque. The presence of putative progenitor cells of mesenchymal lineages was confirmed by a fibroblast colony-forming assay, with approximately 20 colonies counted per 10⁶ BMMC seeded (Fig. 1).

Clinical presentation
Three individuals with severe asthma were included in the study and periodically followed up for 1 year after BMMC transplantation (2 × 10⁷ cells/patient). All were women and had a mean age of 55 years (range 50–58 years) and body mass index (BMI) of 29.5 kg m⁻² (range
22.4–34.1 kg m⁻²) at intervention. Although all three patients had severe asthma, considerable heterogeneity in baseline clinical parameters and signs was observed among them (Table 3).

**Patient 1** was a 50-year-old woman (height 1.55 m, weight 82 kg, BMI 34.1 kg m⁻²) with severe steroid-dependent allergic asthma who demonstrated no therapeutic response to omalizumab. The patient had never smoked. Disease onset had occurred in early childhood, with remission from age 15–25. The patient had a history of severe pulmonary exacerbations requiring mechanical ventilation and tracheostomy, despite regular treatment with high-dose oral and inhaled corticosteroids and LABA. In August 2015, the patient underwent bone marrow aspiration and received a single dose of autologous BMMCs intravenously. Measured variables were performed before treatment and periodically up to 1 year after BMMC transplantation (Table 3). Whole-body ⁹⁹mTc-BMMC scintigraphy was performed 2 h after administration and demonstrated a normal biodistribution of labeled cells, with greater uptake in the liver, lungs (especially the right), heart, blood pool, kidneys, and bladder (Fig. 2). Over the following days, the patient experienced improvement of respiratory symptoms but developed sinus tachycardia, requiring a reduction in LABA dose. A mild increase in ventilation of all zones of the right lung was also observed 120 days after BMMC transplantation. Asthma control was successfully achieved with half of the prior dose of inhaled corticosteroids and LABA for up to 12 months after BMMC transplantation. Asthma control was successfully achieved with half of the prior dose of inhaled corticosteroids and LABA for up to 12 months after BMMC transplantation. Self-perceived QoL score significantly improved on day 7 after the procedure and remained steady over 1 year of follow-up (Fig. 3). Lung function and 6MWD measurements remained stable throughout.

**Patient 2** was a 58-year-old woman (height 1.53 m, weight 75 kg, BMI 32.0 kg m⁻²) with severe steroid-dependent allergic asthma who also failed to respond to omalizumab. Disease onset had occurred in early childhood, with remission from age 15–25. The patient had a history of severe pulmonary exacerbations requiring mechanical ventilation and tracheostomy, despite regular treatment with high-dose oral and inhaled corticosteroids and LABA. In August 2015, the patient underwent bone marrow aspiration and received a single dose of autologous BMMCs intravenously. Measured variables were performed before treatment and periodically up to 1 year after BMMC transplantation (Table 3). Whole-body ⁹⁹mTc-BMMC scintigraphy was performed 2 h after administration and demonstrated a normal biodistribution of labeled cells, with greater uptake in the liver, lungs (especially the right), heart, blood pool, kidneys, and bladder (Fig. 2). Over the following days, the patient experienced improvement of respiratory symptoms but developed sinus tachycardia, requiring a reduction in LABA dose. A mild increase in ventilation of all zones of the right lung was also observed 120 days after BMMC transplantation. Asthma control was successfully achieved with half of the prior dose of inhaled corticosteroids and LABA for up to 12 months after BMMC transplantation. Self-perceived QoL score significantly improved on day 7 after the procedure and remained steady over 1 year of follow-up (Fig. 3). Lung function and 6MWD measurements remained stable throughout.

---

**Table 1** Flow cytometry analysis of total bone marrow cells

| CD markers | Phenotype                          | Percentage |
|------------|------------------------------------|------------|
| CD45⁻/CD34⁺/SSC⁻ | Hematopoietic stem cells          | 0.88       |
| CD45⁻/CD34⁻/CD19⁻ | B cell progenitors                | 3.26       |
| CD45⁻/CD34⁻/CD64⁻CD14⁻ | Promonocytes                     | 0.88       |
| CD105⁺CD90⁻/CD73⁺CD45⁻CD34⁻ | Mesenchymal stromal cells         | 0.1        |
| FSC⁻SSC⁻CD45⁻CD71⁻CD36⁺ | Erythroblasts                    | 8.1        |
| CD45⁻CD34⁻CD64⁻CD14⁺ | Monocytes                        | 2.92       |
| CD45⁻CD34⁻CD3⁻ | T lymphocytes                    | 14.13      |
| CD45⁻CD3⁻CD4⁻ | Helper T cells                   | 5.16       |
| CD45⁻CD3⁻CD8⁻ | Cytotoxic T cells                | 4.33       |
| CD45⁻CD3⁻CD19⁻ | B cells                          | 3.2        |
| CD45⁻CD56⁺ | NK cells                         | 1.2        |
| CD45⁻SSC⁻ | Neutrophils                      | 69.56      |

**Table 2** Flow cytometry analysis of BMMC cell fraction

| CD markers | Phenotype                          | Percentage |
|------------|------------------------------------|------------|
| CD45⁻/CD34⁺/SSC⁻ | Hematopoietic stem cells          | 1.83       |
| CD45⁻/CD34⁻/CD19⁻ | B cell progenitors                | 5.6        |
| CD45⁻CD34⁻CD64⁻CD14⁻ | Promonocytes                     | 4.27       |
| CD105⁺CD90⁻/CD73⁺CD45⁻CD34⁻ | Mesenchymal stromal cells         | 0.07       |
| FSC⁻SSC⁻CD45⁻CD71⁻CD36⁺ | Erythroblasts                    | 6.46       |
| CD45⁻CD34⁻CD64⁻CD14⁺ | Monocytes                        | 9.6        |
| CD45⁻CD3⁻CD3⁻ | T lymphocytes                    | 35.53      |
| CD45⁻CD3⁻CD4⁻ | Helper T cells                   | 12.96      |
| CD45⁻CD3⁻CD8⁻ | Cytotoxic T cells                | 9.46       |
| CD45⁻CD3⁻CD19⁻ | B cells                          | 5.6        |
| CD45⁻CD56⁺ | NK cells                         | 4.46       |

**Abbreviations:** CD cluster of differentiation, FSC forward scatter, NK natural killer, SSC side scatter
childhood; there had been no remission. The patient had mild bronchiectasis without chronic infection and had never smoked. IgE testing for *Aspergillus fumigatus* was negative on multiple occasions. The patient was on regular high-dose oral and inhaled corticosteroids plus LABA and had a history of multiple hospital admissions due to pulmonary exacerbations. In November 2015, bone marrow aspiration was performed, and the patient received a single dose of autologous BMMCs intravenously and was periodically followed for a year (Table 3). Corticosteroids and LABA were continued. Whole-body ⁹⁹ᵐTc-BMMC scintigraphy performed 2 h after cell infusion demonstrated a normal biodistribution of labeled cells, with greater uptake in the liver, lungs, heart, blood

**Table 3 Clinical parameters**

| Patient | Parameters | Visit (days) | D−28 (baseline) | D + 7 | D + 30 | D + 60 | D + 120 | D + 180 | D + 360 |
|---------|------------|--------------|-----------------|-------|--------|--------|--------|--------|--------|
| 1       | FVC (L)    |              | 2.23            | 2.18  | 2.04   | 2.06   | 1.87   | 2.05   | 1.89   |
|         | FVC (%)    |              | 76              | 75    | 70     | 70     | 64     | 70     | 65     |
|         | FEV₁, pre-BD (L) |          | 1.5            | 1.6   | 1.48   | 1.57   | 1.5    | 1.56   | 1.46   |
|         | FEV₁ (%)   |              | 62             | 66    | 61     | 65     | 62     | 65     | 61     |
|         | 6MWT (m)   |              | 273            | 273   | 291    | 276    | 240    | 269    | 294    |
| 2       | FVC (L)    |              | 1.99           | 2.00  | 2.40   | 1.72   | 1.78   | 1.85   | 1.77   |
|         | FVC (%)    |              | 74             | 74    | 89     | 64     | 66     | 68     | 66     |
|         | FEV₁, pre-BD (L) |          | 0.88           | 0.95  | 1.08   | 0.65   | 0.71   | 0.76   | 0.66   |
|         | FEV₁ (%)   |              | 41             | 44    | 50     | 30     | 33     | 35     | 31     |
|         | 6MWT (m)   |              | 412            | *     | 380    | 255    | 310    | 176    | 324    |
| 3       | FVC (L)    |              | 1.89           | 2.10  | 1.87   | 1.99   | 1.94   | 1.68   | 1.86   |
|         | FVC (%)    |              | 64             | 72    | 64     | 68     | 66     | 57     | 64     |
|         | FEV₁, pre-BD (L) |          | 0.83           | 0.85  | 0.77   | 0.87   | 0.86   | 0.78   | 0.85   |
|         | FEV₁ (%)   |              | 35             | 36    | 33     | 37     | 37     | 33     | 37     |
|         | 6MWT (m)   |              | 354            | 390   | 380    | 450    | 441    | 360    | 390    |

**Abbreviations:** 6MWT 6-min walk test, BD bronchodilator, FEV₁ forced expiratory volume in 1 s, FVC forced vital capacity

*Missing data*
pool, kidneys, and bladder (Fig. 2). Thirty days after the procedure, asthma control was achieved, and the patient demonstrated better exercise tolerance as well as a reduction in corticosteroid requirements. During the following months, the patient had three pulmonary exacerbations, each requiring an increase in the dose of oral corticosteroids and prescription of antibiotics. No significant changes in ventilation or perfusion from baseline were observed on day 120 post-BMMC transplantation. Over the 1-year follow-up period, her asthma remained partially controlled. Lung function, 6MWD, and self-perceived QoL score improved slightly up to 30 days after BMMC transplantation (Table 3, Fig. 3). On day 60, these parameters declined, which remained stable thereafter.

**Patient 3** was a 58-year-old woman (height 1.58 m, weight 56 kg, BMI 22.4 kg m$^{-2}$) with severe non-allergic asthma. Disease onset occurred at age 47; the patient had never smoked. She had dyspnea with minimal exertion despite regular treatment with high-dose inhaled corticosteroids, LABA, and a long-acting muscarinic antagonist. Severe obstruction was also observed on spirometry, with a positive bronchodilator test. In December 2016, the patient underwent bone marrow aspiration and received a single dose of autologous BMMCs intravenously. Lung function remained stable throughout the follow-up period. Asthma control, QoL score, and 6MWD improved slightly over the first 30 days after BMMC transplantation and remained stable up to day
180 (Table 3, Fig. 3). Thereafter, a mild increase in breathlessness was reported, but without the need to change baseline treatments. At 1-year follow-up, asthma symptoms were partially controlled, and both self-perceived QoL and 6MWD had improved from baseline.

In the first trimester of 2020, all patients were alive, with a significant reduction in the number of hospital admissions during their respective follow-up periods compared to before BMMC transplantation. Patient 2 had a pneumonia episode in 2019, however, recovered well. More recently, both patients 1 and 2 were using only an oral inhalation solution of formoterol fumarate plus budesonide, while patient 3 was using two oral inhalation solutions (formoterol fumarate/beclometasone and tiotropium bromide).

Discussion
This case series describes the effects of a single intravenous dose of autologous BMMCs in three patients with severe asthma. The procedure was well tolerated, and no adverse events related to BMMC transplantation were observed during 1-year follow-up. Although these patients had heterogenous clinical features and signs at baseline, no significant changes were found in lung function tests after BMMC transplantation. Nevertheless, patients 1 and 3 experienced an improvement in self-perceived QoL score in the early post-procedure course, which remained stable throughout the follow-up period. Patient 2 also exhibited an improvement in self-perceived QoL in the early course after BMMC transplantation; however, this patient had a pulmonary exacerbation episode, which resulted in the worsening of QoL scores on day 60, remaining stable thereafter up to day 180. Total bone marrow cells and BMMCs of all patients were characterized using a defined panel of phenotypic markers. Furthermore, the functional characterization of fibroblastic-like cells was confirmed by the presence of putative progenitor cells of mesenchymal lineages.

Preclinical data have demonstrated the great potential of cell-based therapies in modulating inflammatory parameters, including recruitment and polarization of immune cells and production of cytokines/chemokines and growth factors [3–5]. Although MSC administration has been more extensively investigated for a wide range of diseases, we specifically evaluated the effects of BMMC transplantation in patients with severe asthma, as these cells were associated with greater reduction in lung tissue abnormalities and fibrosis in a murine model of ovalbumin-induced allergic asthma [10]. Furthermore, in a model Aspergillus hyphal extract-induced allergic asthma, reduction in inflammation and airway hyperresponsiveness was triggered by CD11b+ (monocytes, macrophages, dendritic cells) and Sca-1+ (MSCs) cells present in the pool of BMMCs. Such findings demonstrated that therapeutic effects were resulting from the balance between cell types rather than strictly from MSCs [6]. Autologous BMMCs can also be administered on the same day of harvesting, thus preventing further costs related to cell culture procedures and potential complications of human leukocyte antigen mismatch. A peripheral vein was used for BMMC transplantation, since the procedure could be easily performed without the need of intubation for bronchoscopy. Intravenous
administration has demonstrated a good safety profile for delivery of either BMMCs or MSCs in experimental models [6, 7, 9, 17–20]. Even though a systemic route was used in the cases described herein, these cells are efficiently delivered to the lungs as they are subject to a first-pass effect [21].

The best cell dosing strategy to achieve optimal therapeutic outcomes in respiratory diseases is still unknown, and only a few dose-escalation clinical trials have been performed to date [3–5]. We used a fixed dose of $2 \times 10^7$ BMMCs per patient, regardless of body weight; this dose was selected on the basis of clinical studies previously evaluating the safety and feasibility of BMMCs in patients with silicosis or ischemic stroke [12, 13]. Moreover, we aspirated the volume of the bone marrow (~150 mL) from which the maximum number of cells was harvested and injected. During the follow-up period, one patient demonstrated early improvement in self-perception of QoL, followed by a pulmonary exacerbation episode some months later, which resulted in a decline in QoL score. These adverse events were most likely related to disease progression and severity, as this patient already had a history of multiple hospital admissions due to pulmonary exacerbations. The remaining two patients demonstrated improvement in QoL score which remained throughout the study, although no therapeutic effects on lung function were noted. The safety profile found in this early-stage study is encouraging for future evaluations of whether administration of increasing doses of BMMCs may result in improved lung function without eliciting adverse effects in patients with severe asthma. Furthermore, a single dose of either BMMCs or MSCs has demonstrated therapeutic effects in experimental studies, but repeated cell-based therapy yielded greater effects—either by preventing disease progression or by further mitigating inflammation and remodeling—in animal models of silicosis, elastase-induced emphysema, and house dust mite-induced allergic asthma [7, 22, 23]. Future large-scale trials should be conducted to comparatively determine the potential efficacy of single-dose versus repeated cell-based therapy in patients with severe asthma.

To track BMMCs after systemic administration, cells were labeled with $^{99m}$Tc. This radioisotope has a short half-life (approximately 6 h) but allows efficient cell labeling for early-course tracking after administration, as well as a lower radiation burden for BMMCs and patients compared to other isotopes [13, 24, 25]. Although the chemical compounds used in labeling may cause cell damage, regardless of which technique is used, we did not observe any significant reduction in either BMMC or MSC viability in previous experimental and clinical studies using $^{99m}$Tc [12, 17, 18, 20]. Two hours after systemic administration of $^{99m}$Tc-BMMCs, these cells were localized in several organs, but a considerable uptake was observed in the lungs, possibly due to circulating chemoattractant mediators and first-pass effects. It remains to be elucidated whether and how long BMMCs would persist in the lungs and other organs, as therapeutic effects of cell-based therapy in experimental models have been attributable to paracrine/endocrine actions without the need of cell engraftment [3–5].

No deaths or adverse events related to BMMC transplantation occurred during the procedure, nor during the follow-up period. Patients 1 and 3 reported improvement in QoL scores in the early post-procedure course, and their clinical features remained stable over 1-year follow-up. Although lung function and 6MWT did not improve significantly, a mild increase in ventilation of the right lung was observed in patient 1 120 days after BMMC transplantation. Interestingly, this patient also exhibited better baseline lung function values, which suggests that therapeutic outcomes might differ depending on disease severity during and after the intervention.

Our group is the first evaluating the effects of a single dose of BMMCs in patients with severe asthma. Limitations of this study include the small sample size, lack of a placebo-controlled, randomized design, and measurements of inflammatory biomarkers. Furthermore, as our primary aim was to evaluate the safety of a single dose of BMMCs, the design was underpowered for efficacy. Although a 1-year follow-up period is not long enough to enable definitive conclusions, the safety profile of BMMC transplantation observed herein is encouraging to pursue large-scale clinical trials in patients with severe asthma.

**Conclusion**

A single intravenous dose of autologous BMMCs appears to be safe and improves self-perceived QoL in the early course after the procedure. These results provide a basis for subsequent clinical investigations of BMMCs or even other cell types in patients with severe asthma.

**Acknowledgements**

The authors thank Mrs. Moira Elizabeth Schottler (Rio de Janeiro) and Mr. Filipe Vasconcellos (São Paulo), Brazil, for their assistance in editing the manuscript and Mrs. Lilian de Carvalho Rodrigues for her help in patient contact.

**Authors’ contributions**

F.S.A., A.S.M.A., and A.P.C.: collection and/or assembly of data, data analysis and interpretation, and provision of patient monitoring; S.L.S. and R.C.S.G.: imaging analysis and interpretation; M.L.P, F.F.C., D.G.X., K.D.A., L.F., R.C.S.G., A.B.S.S., and M.C.P.P.L.: data analysis and interpretation; M.M.M., P.R.M.R., and J.R.L.S.: conception and design, data analysis, and interpretation. All authors approved the final version of the manuscript.

**Funding**

This study is supported by the Brazilian Council for Scientific and Technological Development (CNPq) [grant number 421067/2016-0, 2016], the Rio de Janeiro State Research Foundation (FAPERJ) [grant number E-26/210.713/2014, 2016], and the National Institute of Science and Technology.
for Regenerative Medicine (INCT-REGENERA) [grant number 465656/2014-5, 2017].

Availability of data and materials
The data that support the findings of this study are available from the corresponding author upon reasonable request.

Ethics approval and consent to participate
The study protocol and informed consent form were approved by the Brazilian National Research Ethics Committee (CONEP; study ID number: 06503212.3.0000.5257). All patients signed the informed consent form to participate in this study and allow the publication of the results.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Author details
1Institute of Thoracic Medicine, Clementino Fraga Filho University Hospital, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. 2Department of Radiology, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. 3Laboratory of Pulmonary Investigation, Carlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. 4National Institute of Science and Technology for Regenerative Medicine, Rio de Janeiro, Brazil. 5Laboratory of Cellular and Molecular Physiology, Carlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. 6Laboratory of Cellular and Molecular Cardiology, Carlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. 7Department of Clinical Hematology, Clementino Fraga Filho University Hospital, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. 8. Abreu SC, Antunes MA, de Castro JC, et al. Bone marrow-derived mononuclear cells vs. mesenchymal stromal cells in experimental allergic asthma. Respir Physiol Neurobiol. 2013;187:190–8. https://doi.org/10.1016/j.resp.2013.03.014.

9. Malone ES, Oyama LA, Jericó PC, et al. Effects of mesenchymal stromal cells play a role the oxidant/antioxidant balance in a murine model of asthma. Allergol Immunopathol (Madr). 2018;46:136–43. https://doi.org/10.1016/j.allerj.2017.06.003.

10. Abreu SC, Antunes MA, de Castro JC, et al. Bone marrow-derived mononuclear cells vs. mesenchymal stromal cells in experimental allergic asthma. Respir Physiol Neurobiol. 2013;187:190–8. https://doi.org/10.1016/j.resp.2013.03.014.

11. Malaquias MAS, Oyama LA, Jericó PC, et al. Effects of mesenchymal stromal cells play a role the oxidant/antioxidant balance in a murine model of asthma. Allergol Immunopathol (Madr). 2018;46:136–43. https://doi.org/10.1016/j.allerj.2017.06.003.

12. Morales MM, Souza SA, Loivos LP, et al. Pilot safety study of intrabronchial instillation of bone marrow-derived mononuclear cells in patients with silicosis. BMC Pulm Med. 2015;15:66. https://doi.org/10.1186/s12890-015-0061-8.

13. Barbosa da Fonseca LM, Gutfllen B, Rosado de Castro PH, et al. Migration and homing of bone-marrow mononuclear cells in chronic ischemic stroke after intra-arterial injection. Exp Neurol. 2010;221:122–8. https://doi.org/10.1016/j.expneurol.2009.10.101.

14. Martin MT, Oliveira OS, Souza FC, et al. A safety and feasibility study of cell therapy in diluted cardiomyopathy. Braz J Med Biol Res. 2014;47:989–95. https://doi.org/10.1590/S0100-879X2014000700093.

15. Ohno Y, Hatabu H, Higashino T, et al. Dynamic perfusion MRI versus perfusion scintigraphy: prediction of postoperative lung function in patients with lung cancer. AJR Am J Roentgenol. 2004;182:73–8. https://doi.org/10.2214/ajr.182.1.1820073.

16. Jones PW, Quirk FH, Bayevstock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory Questionnaire. Am Rev Respir Dis. 1992;145:1321–7. https://doi.org/10.1164/ajrccm/145.6.1321.

17. Lopes-Pacheco M, Ventura TG, de Oliveira HD, et al. Infusion of bone marrow mononuclear cells reduces lung fibrosis but not inflammation in the late stages of murine silicosis. PLoS One. 2014:e109982. https://doi.org/10.1371/journal.pone.0109982.

18. de Oliveira HD, de Melo EBB, Silva JD, et al. Therapeutic effects of bone marrow-derived mononuclear cells from healthy or silicotic donors on recipient silicosis mice. Stem Cell Res Ther. 2017;8:259. https://doi.org/10.1186/s13287-017-0699-7.

19. Suda S, Kuroki Y, Kuroki K, et al. Autologous bone marrow mononuclear cells exert broad effects on short- and long-term biological and functional outcomes in rodents with intracerebral hemorrhage. Stem Cells Dev. 2015;24:2756–66. https://doi.org/10.1089/scd.2015.0107.

20. Silva JD, Lopes-Pacheco M, de Castro LL, et al. Eicosapentaenoic acid potentiates the therapeutic effects of adipose tissue-derived mesenchymal stromal cells on lung and distal organ injury in experimental sepsis. Stem Cell Res Ther. 2019;10:364. https://doi.org/10.1186/s13287-019-1363-z.

21. Fischer UM, Harting MT, Jimenez F, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev. 2009;18:683–92. https://doi.org/10.1089/scd.2008.0253.

22. Lopes-Pacheco M, Xisto DG, Omellas FM, et al. Repeated administration of bone marrow-derived cells prevents disease progression in experimental silicosis. Cell Physiol Biochem. 2013;32:1681–94. https://doi.org/10.1159/000356603.

23. Poggio HA, Antunes MA, Rocha NN, et al. Impact of one versus two doses of mesenchymal stromal cells on lung and cardiovascular repair in experimental emphysema. Stem Cell Res Ther. 2018;9:206. https://doi.org/10.1186/s13287-018-1043-6.

24. Fischer UM, Harting MT, Jimenez F, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev. 2009;18:683–92. https://doi.org/10.1089/scd.2008.0253.

25. Rosado-de-Castro PH, Pimentel-Coelho PM, Gutfllen B, et al. Radiopharmaceutical stem cell tracking for neurological diseases. Biomed Res Int 2014; 417091. doi: https://doi.org/10.1155/2014/417091.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.